类风湿关节炎患者接种第三剂mRNA新冠疫苗后的体液与细胞免疫应答
该观察性研究纳入60例已接种两剂mRNA新冠疫苗的类风湿关节炎患者,在第三剂前后采集血样,并与50名健康对照比较。第三剂后4周,43%抗S抗体和62%抗RBD抗体达到正常体液应答,停用或继续DMARDs者抗体水平无差异;活化CD4 T细胞频率较第三剂前显著升高,但抗体变化与T细胞变化不相关。
要点
- 第三剂mRNA疫苗后4周,43%患者抗S抗体、62%患者抗RBD抗体达到健康对照均值1个标准差内的正常应答。
- 是否停用DMARDs与抗体水平无差异。
- 活化CD4 T细胞频率第三剂后较前显著升高,但抗体变化与T细胞变化不相关。
核心结论
- 使用DMARDs的类风湿关节炎患者在完成基础疫苗系列后接种第三剂,病毒特异性IgG水平显著升高,但不足三分之二达到与健康对照相似的体液应答。
- 体液与细胞免疫变化不相关。
研究设计与样本
- 观察性研究,2021年纳入已接种两剂mRNA新冠疫苗、准备接种第三剂的类风湿关节炎患者,受试者自我报告停用或继续DMARDs,第三剂前及第三剂后4周采集血样。
- 共60例类风湿关节炎患者,平均年龄63岁,88%为女性;57%在第三剂前后停用至少一种DMARDs;50名健康对照提供血样。
主要发现
- 第三剂后第4周,43%(抗S抗体)和62%(抗RBD抗体)的患者达到正常体液应答,定义为ELISA值在健康对照均值1个标准差内。
- 基于是否停用DMARDs,未观察到抗体水平差异。
- 活化CD4 T细胞的中位频率在第三剂后较第三剂前显著升高。
- 抗体水平变化与活化CD4 T细胞频率变化不相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Disease-modifying anti-rheumatic drugs (DMARDs) that treat rheumatoid arthritis (RA) may reduce immune responses to COVID-19 vaccination. We compared humoral and cell-mediated immunity before and after a 3rd dose of mRNA COVID vaccine in RA subjects. METHODS: RA patients that received 2 doses of mRNA vaccine enrolled in an observational study in 2021 before receiving a 3rd dose. Subjects self-reported holding or continuing DMARDs. Blood samples were collected pre- and 4 weeks after the 3rd dose. 50 healthy controls provided blood samples. Humoral response was measured with in-house ELISA assays for anti-Spike IgG (anti-S) and anti-receptor binding domain IgG (anti-RBD). T cell activation was measured after stimulation with SARS-CoV-2 peptide. Spearman's correlations assessed the relationship between anti-S, anti-RBD, and frequencies of activated T cells. RESULTS: Among 60 subjects, mean age was 63 years and 88% were female. 57% of subjects held at least 1 DMARD around the 3rd dose. 43% (anti-S) and 62% (anti-RBD) had a normal humoral response at week 4, defined as ELISA within 1 standard deviation of the healthy control mean. No differences in antibody levels were observed based on holding DMARDs. Median frequency of activated CD4 T cells was significantly greater post- vs. pre-3rd dose. Changes in antibody levels did not correlate with change in frequency of activated CD4 T cells. CONCLUSION: Virus-specific IgG levels significantly increased in RA subjects using DMARDs after completing the primary vaccine series, though fewer than two-thirds achieved a humoral response like healthy controls. Humoral and cellular changes were not correlated.
引用
- Tedeschi SK, Solomon DH, Chen Y, et al. Humoral and cellular immune responses in persons with rheumatoid arthritis after a third dose of mRNA COVID-19 vaccine. Semin Arthritis Rheum. 2023. PMID: 36796211. doi:10.1016/j.semarthrit.2023.152177
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。